vs
ICU MEDICAL INC（ICUI）与LOUISIANA-PACIFIC CORP（LPX）财务数据对比。点击上方公司名可切换其他公司
LOUISIANA-PACIFIC CORP的季度营收约是ICU MEDICAL INC的1.0倍（$566.0M vs $540.7M），LOUISIANA-PACIFIC CORP净利率更高（-1.4% vs -2.9%，领先1.5%），ICU MEDICAL INC同比增速更快（-14.1% vs -16.9%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-8.0M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -11.6%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
ICUI vs LPX — 直观对比
营收规模更大
LPX
是对方的1.0倍
$540.7M
营收增速更快
ICUI
高出2.7%
-16.9%
净利率更高
LPX
高出1.5%
-2.9%
自由现金流更多
ICUI
多$44.0M
$-8.0M
两年增速更快
ICUI
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $566.0M |
| 净利润 | $-15.7M | $-8.0M |
| 毛利率 | 37.5% | 15.0% |
| 营业利润率 | 1.0% | -1.6% |
| 净利率 | -2.9% | -1.4% |
| 营收同比 | -14.1% | -16.9% |
| 净利润同比 | 34.0% | -112.9% |
| 每股收益（稀释后） | $-0.63 | $-0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUILPX
| Q4 25 | $540.7M | $566.0M | ||
| Q3 25 | $537.0M | $663.0M | ||
| Q2 25 | $548.9M | $755.0M | ||
| Q1 25 | $604.7M | $724.0M | ||
| Q4 24 | $629.8M | $681.0M | ||
| Q3 24 | $589.1M | $722.0M | ||
| Q2 24 | $596.5M | $814.0M | ||
| Q1 24 | $566.7M | $724.0M |
净利润ICUILPX
| Q4 25 | $-15.7M | $-8.0M | ||
| Q3 25 | $-3.4M | $9.0M | ||
| Q2 25 | $35.3M | $54.0M | ||
| Q1 25 | $-15.5M | $91.0M | ||
| Q4 24 | $-23.8M | $62.0M | ||
| Q3 24 | $-33.0M | $90.0M | ||
| Q2 24 | $-21.4M | $160.0M | ||
| Q1 24 | $-39.5M | $108.0M |
毛利率ICUILPX
| Q4 25 | 37.5% | 15.0% | ||
| Q3 25 | 37.4% | 19.5% | ||
| Q2 25 | 37.9% | 23.6% | ||
| Q1 25 | 34.7% | 27.2% | ||
| Q4 24 | 36.1% | 23.8% | ||
| Q3 24 | 34.8% | 26.7% | ||
| Q2 24 | 34.8% | 32.3% | ||
| Q1 24 | 32.7% | 29.6% |
营业利润率ICUILPX
| Q4 25 | 1.0% | -1.6% | ||
| Q3 25 | 2.6% | 2.7% | ||
| Q2 25 | 1.9% | 10.6% | ||
| Q1 25 | 2.1% | 16.6% | ||
| Q4 24 | 6.0% | 11.0% | ||
| Q3 24 | 1.4% | 16.1% | ||
| Q2 24 | 1.3% | 23.8% | ||
| Q1 24 | -1.9% | 20.0% |
净利率ICUILPX
| Q4 25 | -2.9% | -1.4% | ||
| Q3 25 | -0.6% | 1.4% | ||
| Q2 25 | 6.4% | 7.2% | ||
| Q1 25 | -2.6% | 12.6% | ||
| Q4 24 | -3.8% | 9.1% | ||
| Q3 24 | -5.6% | 12.5% | ||
| Q2 24 | -3.6% | 19.7% | ||
| Q1 24 | -7.0% | 14.9% |
每股收益（稀释后）ICUILPX
| Q4 25 | $-0.63 | $-0.12 | ||
| Q3 25 | $-0.14 | $0.13 | ||
| Q2 25 | $1.43 | $0.77 | ||
| Q1 25 | $-0.63 | $1.30 | ||
| Q4 24 | $-0.97 | $0.90 | ||
| Q3 24 | $-1.35 | $1.28 | ||
| Q2 24 | $-0.88 | $2.23 | ||
| Q1 24 | $-1.63 | $1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $292.0M |
| 总债务越低越好 | — | $348.0M |
| 股东权益账面价值 | $2.1B | $1.7B |
| 总资产 | $4.1B | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资ICUILPX
| Q4 25 | — | $292.0M | ||
| Q3 25 | — | $316.0M | ||
| Q2 25 | — | $333.0M | ||
| Q1 25 | — | $256.0M | ||
| Q4 24 | $308.6M | $340.0M | ||
| Q3 24 | $312.5M | $346.0M | ||
| Q2 24 | $302.6M | $317.0M | ||
| Q1 24 | $251.4M | $244.0M |
总债务ICUILPX
| Q4 25 | — | $348.0M | ||
| Q3 25 | — | $348.0M | ||
| Q2 25 | — | $348.0M | ||
| Q1 25 | — | $348.0M | ||
| Q4 24 | — | $348.0M | ||
| Q3 24 | — | $347.0M | ||
| Q2 24 | — | $347.0M | ||
| Q1 24 | — | $347.0M |
股东权益ICUILPX
| Q4 25 | $2.1B | $1.7B | ||
| Q3 25 | $2.1B | $1.7B | ||
| Q2 25 | $2.1B | $1.7B | ||
| Q1 25 | $2.0B | $1.7B | ||
| Q4 24 | $2.0B | $1.7B | ||
| Q3 24 | $2.0B | $1.7B | ||
| Q2 24 | $2.0B | $1.7B | ||
| Q1 24 | $2.1B | $1.6B |
总资产ICUILPX
| Q4 25 | $4.1B | $2.6B | ||
| Q3 25 | $4.1B | $2.6B | ||
| Q2 25 | $4.1B | $2.7B | ||
| Q1 25 | $4.2B | $2.6B | ||
| Q4 24 | $4.2B | $2.6B | ||
| Q3 24 | $4.3B | $2.6B | ||
| Q2 24 | $4.3B | $2.5B | ||
| Q1 24 | $4.3B | $2.5B |
负债/权益比ICUILPX
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $67.0M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-8.0M |
| 自由现金流率自由现金流/营收 | 6.6% | -1.4% |
| 资本支出强度资本支出/营收 | 4.6% | 13.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $91.0M |
8季度趋势，按日历期对齐
经营现金流ICUILPX
| Q4 25 | $60.6M | $67.0M | ||
| Q3 25 | $56.7M | $89.0M | ||
| Q2 25 | $11.2M | $162.0M | ||
| Q1 25 | $51.3M | $64.0M | ||
| Q4 24 | $40.2M | $105.0M | ||
| Q3 24 | $36.1M | $183.0M | ||
| Q2 24 | $82.0M | $212.0M | ||
| Q1 24 | $45.8M | $105.0M |
自由现金流ICUILPX
| Q4 25 | $36.0M | $-8.0M | ||
| Q3 25 | $27.6M | $5.0M | ||
| Q2 25 | $-8.5M | $94.0M | ||
| Q1 25 | $36.7M | $0 | ||
| Q4 24 | $16.1M | $43.0M | ||
| Q3 24 | $16.2M | $139.0M | ||
| Q2 24 | $62.5M | $176.0M | ||
| Q1 24 | $29.9M | $64.0M |
自由现金流率ICUILPX
| Q4 25 | 6.6% | -1.4% | ||
| Q3 25 | 5.1% | 0.8% | ||
| Q2 25 | -1.5% | 12.5% | ||
| Q1 25 | 6.1% | 0.0% | ||
| Q4 24 | 2.6% | 6.3% | ||
| Q3 24 | 2.7% | 19.3% | ||
| Q2 24 | 10.5% | 21.6% | ||
| Q1 24 | 5.3% | 8.8% |
资本支出强度ICUILPX
| Q4 25 | 4.6% | 13.3% | ||
| Q3 25 | 5.4% | 12.7% | ||
| Q2 25 | 3.6% | 9.0% | ||
| Q1 25 | 2.4% | 8.8% | ||
| Q4 24 | 3.8% | 9.1% | ||
| Q3 24 | 3.4% | 6.1% | ||
| Q2 24 | 3.3% | 4.4% | ||
| Q1 24 | 2.8% | 5.7% |
现金转化率ICUILPX
| Q4 25 | — | — | ||
| Q3 25 | — | 9.89× | ||
| Q2 25 | 0.32× | 3.00× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 1.69× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
